Pharma BD Deal Intelligence
Takeda Pharmaceutical Company Ltd. / Nimbus Lakshmi
2022 · Acquisition/Merger · $6.0B · Complete
Announcement Sentiment
90
Strongly positive
Outcome Score
82
Worked — the deal delivered on its rationale.
Takeda acquired Nimbus Lakshmi for $6B for TYK2 inhibitor for autoimmune diseases.
Key facts
- Announced Dec 13, 2022
- Closed Feb 08, 2023
- Deal value $6.0B
- Deal type Acquisition/Merger
- Therapeutic area Dermatology, Immunology
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals